Study shows first-of-its kind gene therapy can restore vision to people with an inherited retinal disorder
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.
Patients in the study had a condition called Leber congenital amaurosis (LCA), which begins in infancy and progresses slowly, eventually causing complete blindness. This new, first-of-its kind gene therapy is currently under review by the U.S. Food and Drug Administration for potential approval this year. There are currently no treatments available for inherited retinal diseases.
Ophthalmologist Stephen R. Russell, M.D., of the University of Iowa, is one of the lead researchers for this pioneering treatment. Data from the first randomized, controlled, phase 3 study showed that 27 of 29 treated patients (93 percent) experienced meaningful improvements in their vision, enough that they could navigate a maze in low to moderate light. They also showed improvement in light sensitivity and peripheral vision, which are two visual deficits these patients experience.
Approval could open the door for other gene therapies that could eventually treat the more than 225 genetic mutations known to cause blindness. It could be applied to retinitis pigmentosa, another inherited retinal disease caused by a defective gene. Or in the future, gene therapy could possibly provide key proteins needed to restore vision in more common diseases such as age-related macular degeneration.
LCA is rare, affecting about 1 in 80,000 individuals. It can be caused by one or more of 19 different genes. The treatment, called voretigene neparvovec (Luxturna, Spark Therapeutics), involves a genetically modified version of a harmless virus. The virus is modified to carry a healthy version of the gene into the retina. Doctors inject billions of modified viruses into both of a patient’s eyes.
Treatment doesn’t restore normal vision. It does, however, allow patients to see shapes and light, allowing them to get around without a cane or a guide dog. It is unclear how long the treatment will last, but so far, most patients have maintained their vision for two years.
More than 200 patients with LCA have participated in gene therapy trials since 2007.
However, no gene therapy has gotten this close to FDA approval for retinal disease or any other eye disease. In October, an advisory committee to the FDA unanimously endorsed the treatment. The FDA isn’t obligated to follow the recommendations of its advisory committees, but it usually does. The agency is expected to make its decision no later than January 2018.
The Latest on: Gene therapy
Staggering prices slow insurers’ coverage of gene therapy
on July 18, 2018 at 7:47 am
Your article was successfully shared with the contacts you provided. The therapy involves collecting patients’ own T cells, a type of white blood cell, genetically modifying them, and then infusing th... […]
Gene Therapy Market to 2025 - bluebird bio, uniQure N.V, AveXis, Vineti, Solid Biosciences, Spark Therapeutics, CHIMERON BIO
on July 18, 2018 at 12:47 am
The growth of the gene therapy market is regulated due to various reason which includes the rapid involvement of synthetically modified gene to treat various diseases, it helps in designing the person... […]
Fetal gene therapy prevents fatal neurodegenerative disease
on July 17, 2018 at 10:22 pm
A fatal neurodegenerative condition known as Gaucher disease can be prevented in mice following fetal gene therapy, finds a new study led by UCL, the KK Women’s and Children’s Hospital and National Un... […]
Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
on July 17, 2018 at 1:16 pm
Pfizer Inc. PFE announced that it initiated a phase III, lead-in study of an experimental gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B. Fidanacogene elaparvovec, a ... […]
Gene editing may enhance CAR T-cell therapy for hematologic malignancies
on July 17, 2018 at 1:11 pm
Researchers at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have used gene editing technology known as CRISPR to engineer human T cells to ... […]
Voyager advancing gene therapy for Parkinson's, Phase 2 data may be sufficient for U.S. marketing application
on July 17, 2018 at 8:38 am
Based on FDA feedback, Voyager Therapeutics (NASDAQ:VYGR) says it maintains its plan to submit a BLA seeking approval for gene therapy VY-AADC based on Phase 2 data. It says it will include Phase 3 re... […]
Fetal Gene Therapy Prevents Fatal Form of Gaucher Disease
on July 17, 2018 at 7:03 am
Study shows Gaucher disease can be prevented in mice following fetal gene therapy. [Cambridge University] Scientists have successfully delivered gene therapy directly to the brains of unborn mouse fet... […]
Pfizer begins late-stage testing of Spark's hemophilia B gene therapy
on July 16, 2018 at 1:16 pm
Pfizer Inc. said Monday it has started late-stage clinical testing of an experimental gene therapy treatment, originally developed by Spark Therapeutics in Philadelphia, for patients with hemophilia B ... […]
Fetal gene therapy could treat genetic diseases in the womb
on July 16, 2018 at 11:14 am
Emboldened by recent success stories of human gene therapy trials in children and infants, researchers are now pushing to treat diseases before birth. Some scientists are excited by the idea of using ... […]
Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls
on July 16, 2018 at 7:52 am
Avrobio Inc (NASDAQ: AVRO), a developer of gene therapy drugs targeting rare lysosomal storage disorders such as Fabry disease, Gaucher disease, Pompe disease and cystinosis, recently offered 5.25 mil... […]
via Google News and Bing News